Endocrine Abstracts

Sorafenib (S) is a reasonably well-tolerated therapy in DTC. A large number of side-effects have been reported. We report our data on the effectiveness and tolerability of S in 6 patients with advanced metastatic epithelial (2 follicular, 1 papillary, 1 insular) and medullary DTCs (52–79 years). In all patients, heart function was evaluated before and during S administration (400 mg/day) together with the objective response rate and changes in serum markers. Underlying he...